Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,275 | -9,091 | -2,115 | -65 | -40 |
| Depreciation Amortization | 206 | 123 | 76 | N/A | N/A |
| Accounts receivable | -377 | N/A | N/A | N/A | N/A |
| Other Working Capital | -112 | 1,152 | 100 | 7 | 3 |
| Other Operating Activity | 563 | 98 | 480 | 2 | 2 |
| Operating Cash Flow | $-12,996 | $-7,718 | $-1,459 | $-56 | $-34 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -351 | -228 | -73 | N/A | N/A |
| Investing Cash Flow | $-351 | $-228 | $-73 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 842 | N/A | N/A |
| Common Stock Issued | 16,472 | 15,580 | 100 | 127 | 61 |
| Other Financing Activity | 0 | 7,870 | 1,005 | 0 | 0 |
| Financing Cash Flow | $16,472 | $23,450 | $1,947 | $127 | $61 |
| Beginning Cash Position | 16,008 | 504 | 89 | 26 | N/A |
| End Cash Position | 19,132 | 16,008 | 504 | 97 | 26 |
| Net Cash Flow | $3,125 | $15,504 | $415 | $71 | $26 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,996 | -7,718 | -1,459 | -56 | -34 |
| Capital Expenditure | -351 | -228 | -73 | N/A | N/A |
| Free Cash Flow | -13,347 | -7,946 | -1,532 | -56 | -34 |